Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Antonio Gutiérrez, Izaskun Zeberio, Pilar Martinez-Barranco, Francisco Javier Peñalver, Sandra Pérez, Daniel Morillo, Xabier Mart N Martitegui, Concepción Nicolás, Ainara Ferrero, Ana Jiménez Ubieto, Mariana Bastos-Oreiro, Julio Dávila-Valls, Maria Victoria Calle Gordo, María Pérez Sala, Guillermo Rodríguez Garcia, Aranzazu Alonso Alonso, Ana Garcia Noblejas, Diana Sanchez Arguello, Teresa Knight Asorey, Maria Angeles Fernandez Fernandez, Javier López Marin, Jaime Perez de Oteyza, Sonia González De Villambrosia, Elena Perez Ceballos, Alejandro Marin, Belén Navarro, Ruben Fernandez Alvarez, Pilar Gómez, Jose Antonio Hueso, Maria Jesus Penarrubia Ponce, Pilar Bravo, Daniel García Belmonte, Haridian De La Nuez Melian, Sara Nistal, Pau Abrisqueta Costa, Fernanda Ibañez, Luis Palomera, Eva Donato, Andrea Provencio Rincon, Maria Stefania Infante, Eva Gonzalez Barca

Blood (2024) 144 (Supplement 1): 2356.

https://doi.org/10.1182/blood-2024-210868

Published: 2024

Journal Articles

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Blood (2024) 144 (Supplement 1): 1698.

https://doi.org/10.1182/blood-2024-201373

Published: 2024

Journal Articles

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Blood (2024) 144 (Supplement 1): 3109.

https://doi.org/10.1182/blood-2024-207895

Published: 2024

Journal Articles

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Blood (2024) 144 (Supplement 1): 1715.

https://doi.org/10.1182/blood-2024-199742

Published: 2024

Journal Articles

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Blood (2024) 144 (Supplement 1): 4478.

https://doi.org/10.1182/blood-2024-212008

Published: 2024

Journal Articles

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Leyre Bento, Fernando Martín Moro, Antonio Gutierrez, Ana Jiménez Ubieto, Alberto López, Blanca Sánchez González, Belén Navarro, Alicia Segura, Mireia Franch, Ana García-Noblejas, Eva Donato, Alejandro Martín García-Sancho, Beatriz De La Cruz, Alfonso Ortiz Algarra, Roberto Trelles-Martínez, Javier López, Carlos Grande, Mariana Bastos-Oreiro

Blood (2024) 144 (Supplement 1): 4471.

https://doi.org/10.1182/blood-2024-203615

Published: 2024

Journal Articles

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Blood (2023) 142 (Supplement 1): 4870.

https://doi.org/10.1182/blood-2023-186594

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Blood (2023) 142 (Supplement 1): 786.

https://doi.org/10.1182/blood-2023-186730

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Blood (2023) 142 (Supplement 1): 4406.

https://doi.org/10.1182/blood-2023-189581

Published: 2023

Journal Articles

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Mariana Bastos-Oreiro, Antonio Gutierrez, Almudena Cabero Martínez, Javier López Jiménez, Paola Sandra Villafuerte Gutierrez, Ana Jimenez-Ubieto, Adolfo De La Fuente, Belén Navarro, Maria Stefania Infante, Raul Cordoba, Jaime Perez De Oteyza, Sonia González de Villambrosia, Raquel Del Campo, Daniel Garcia, Antonio Salar, Juan-Manuel Sancho

Blood (2022) 140 (Supplement 1): 3618–3619.

https://doi.org/10.1182/blood-2022-166027

Published: 2022

Journal Articles

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Blood (2022) 140 (Supplement 1): 9347–9349.

https://doi.org/10.1182/blood-2022-160073

Published: 2022

Journal Articles

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Blood (2022) 140 (Supplement 1): 9342–9344.

https://doi.org/10.1182/blood-2022-163165

Published: 2022

Journal Articles

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Blood (2020) 136 (Supplement 1): 37–40.

https://doi.org/10.1182/blood-2020-134729

Published: 2020

Journal Articles

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Mariana Bastos-Oreiro, MD PhD, Nieves Lopez, Pilar Gomez, Liébana Marta, Laura LLorente, MD, Antonio Gutiérrez, EVA Domingo Domenech, PhD, Maria Jesus Vidal Maceñido, MD, Raquel Del Campo, Leyre Bento, Daniel Garcia, Miriam Santero, Jaime Perez De Oteyza, MD PhD, Belén Navarro, MD, Antonia Rodriguez Izquierdo, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4040.

https://doi.org/10.1182/blood-2019-125813

Published: 2019

Journal Articles

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population

Belén Navarro, MD, Juan Manuel Sancho, MD PhD, Silvina Grasso Cicala, PhD, Mario Spione, PharmD, MSc, Begoña Soler, MD, Pier Luigi Zinzani, MD

Blood (2018) 132 (Supplement 1): 1716.

https://doi.org/10.1182/blood-2018-99-110784

Published: 2018

Journal Articles

Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population

Blood (2018) 132 (Supplement 1): 2938.

https://doi.org/10.1182/blood-2018-99-116562

Published: 2018

Journal Articles

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Pier Luigi Zinzani, MD PhD, Belén Navarro, MD, Juan-Manuel Sancho, MD PhD, Begoña Soler, MD, Silvina Grasso Cicala, PhD, Lorena Yapur, MD, Mario Spione, PharmD, MSc

Blood (2017) 130 (Supplement 1): 5228.

https://doi.org/10.1182/blood.V130.Suppl_1.5228.5228

Published: 2017

Journal Articles

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

Cristina Barrenetxea Lekue, PhD, Clara Alonso Caballero, Laura Hernández Vázquez, Belen Navarro Matilla, Fco Javier Capote Huelva, Dolores Caballero, MD PhD, Noelia Purroy Zuriguel, Irene Leal Martinez, Daniela Caballero Alvarez, Jose Antonio Marquez Navarro, Fernando Marco de Lucas

Blood (2017) 130 (Supplement 1): 5235.

https://doi.org/10.1182/blood.V130.Suppl_1.5235.5235

Published: 2017

Journal Articles

Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Blood (2015) 126 (23): 1508.

https://doi.org/10.1182/blood.V126.23.1508.1508

Published: 2015

Journal Articles

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Blood (2014) 123 (12): 1864–1869.

https://doi.org/10.1182/blood-2013-11-537993

Published: 2014

Includes: Supplemental data

NARROW

Importance of Early Rescue and Relative Dose-Intensity in the Salvage Therapy with Tafasitamab-Lenalidomide in Diffuse Large B-Cell Lymphoma: Real-Life Study in Spain (GELTAMO)

Clinical Characteristics and Outcomes of Patients with Localized Stage High-Grade B-Cell Lymphoma (HGBCL) with or without MYC and BCL2 and/or BCL6 Rearrangements: A Retrospective Study from the Spanish Group Geltamo

Real-World Management Patterns of Acute Toxicity Following Bispecific Antibody Therapy for Patients with B-Cell Lymphoma - the Geltamo (Spanish Lymphoma Group) Experience

Real World Evidence of Second Line Therapy in Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

A New Prognostic Index Including Baseline Clinico-Biological Variables Predicts Outcome in Plasmablastic Neoplasms

Real World Epidemiology and Treatment Strategies of Limited Stage Large B Cell Lymphoma: Spanish Multicenter Geltamo Study

Relinf Registry-Based Analysis Shows Overall Survival Improvement with New Therapies for Relapsed or Refractory Large B-Cell Lymphoma: A Study from the Geltamo Group

Autologous Stem Cell Transplantation Remains a Curative Option As Second Line Treatment for Patients with Relapsed/Refractory Large B Cell Lymphoma: Spanish Multicenter Geth-TC/Geltamo Study

Clinical Characteristics, Treatment Approach and Long-Term Outcomes of 678 Patients with Symptomatic Waldenstrom's Macroglobulinemia: Comprehensive Insights from a Spanish Registry of IgM Gammapathies

Rituximab Maintenance after R-Bendamustine or R-CHOP in First-Line Treatment of Low-Grade Follicular Lymphoma: A Multicentre, Retrospective Study of the Spanih Group Geltamo

Clinical Characterization, Prognosis and Therapeutic Management of 181 Patients with Splenic Marginal Zone Lymphoma (SMZL): Real World Experience of the Geltamo Group

Clinical Features and Outcome of Patients with Castleman Disease Subtypes: A Spanish Multicentric Study of 145 Patients from Geltamo

Infection Risk in Lymphoproliferative Diseases (LPD) Treated with Targeted Drugs. Geltamo Real-Life Experience

Analysis of the Different Surveillance Strategies for Patients with Hodgkin Lymphoma in Clinical Remission after First-Line Treatment. a Study of the Geltamo Group (Spanish lymphoma and autologous transplant group)

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma (aNHL) an Observational Multicentre Retrospective Study in a Real World Population

Peripheral T-Cell Lymphomas in Spain: Profiling Clinical, Phenotypic and Genetic Characteristics in Spanish Population

Evaluation of the Effectiveness and Safety of Pixantrone for the Treatment of Multiply Relapsed or Refractory Aggressive Non Hodgkin B-Cell Lymphoma in an Ongoing International Registry

Preben: Pixantrone, Rituximab, Etoposide and Bendamustine, Spanish Experience in Diffuse Large B-Cell Lymphoma Treatment

Prognostic Factors and Treatment Results in Elderly Patients with Aggressive B-Cell Lymphoma: A Geltamo Observational Study

Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only